Risks of Cardiovascular Disease in Patients Receiving Antiretroviral Therapy for HIV Infection: Implications for Treatment

AIDS Reader

Volumn 14, Issue 2, 2004, Pages 86-95

  Steinhart, Corklin R ^a   Emons, Matthew F ^b  

^a Mercy Hospital Miami   (United States)

^b Zynx Health   (United States)

Author keywords

Antiretroviral therapy; Cardiovascular disease; Dyslipidemia; HAART; HIV ADS

Indexed keywords

ACETYLSALICYLIC ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL; DELAVIRDINE; EFAVIRENZ; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOPINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NELFINAVIR; NEVIRAPINE; NICOTINIC ACID; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; SIMVASTATIN; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL;

AGE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE MANAGEMENT; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; IATROGENIC DISEASE; INFLAMMATION; INSULIN RESISTANCE; LIVER TOXICITY; MUSCLE DISEASE; NONHUMAN; RHABDOMYOLYSIS; RISK FACTOR; RISK REDUCTION;

ANTI-HIV AGENTS; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; HIV INFECTIONS; HUMANS; HYPERLIPIDEMIAS; RISK FACTORS;

EID: 1242269369     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Valenti WM. HIV disease management: new technologies improve outcomes and contain cost. AIDS Reader. 2002;12:64-66.
2. Hoffman C, Jaeger H. Cardiology and AIDS - HAART and the consequences. Ann N Y Acad Sci. 2001;946:130-144.
3. Falusi OM, Adberg JA. HIV and cardiovascular risk factors. AIDS Reader. 2001;11:263-268.
4. Gilleece Y, Nelson M. Does antiretroviral-induced hyperlipidaemia constitute a cardiovascular risk factor? J HIV Ther. 2001;6(2):37-39.
5. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease. Circulation. 2003;107:499-511.
6. Assmann G, Schulte H, Funke H, et al. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998;19(suppl M):M8-M14.
7. Malloy MJ, Kane JP. A risk factor for atherosclerosis: triglyceride-rich lipoproteins. Adv Intern Med. 2001;47:111-136.
8. Jacobs DR, Mebane IL, Bangdiwala SL et al. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol. 1990;131:32-47.
9. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol. 1992;70:733-737.
10. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045-1052.
11. Shor-Posner G, Basit A, Lu Y, et al. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med. 1993;94:515-519.
12. Gattone M, Iacoviello L, Colombo M, et al. Chlamydia pneumoniae and cytomegalovirus seropositivity, inflammatory markers, and the risk of myocardial infarction at a young age. Am Heart J. 2003;142:633-640.
13. Blankenberg S, Rupprecht HJ, Bickel C, et al. Cytomegalovirus infection with interleukin-6 response predicts cardiac mortality in patients with coronary artery disease. Circulation. 2001;103:2915-2921.
14. Jahoor F, Gazzard B, Phillips G, et al. The acute-phase protein response to human imnumodeficiency virus infection in human subjects. Am J Physiol. 1999;276(6 pt 1):E1092-E1098.
15. Wanke C, Lamon-Fava S, Tang A, et al. Risk factors for CHD and coronary calcification in a cohort of HIV-infected subjects. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Abstract 743.
16. Henry K, Zackin R, Dube M, et al. ACTG 5056: C-reactive protein (CRP) levels and cardiovascular risk status for a cohort of HIV-1-infected persons durably suppressed on an indinavir (IDV)-containing regimen. Presented at the 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle. Abstract 694-T.
17. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999,13:F63-F70.
18. Carr A, Samaras, K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
19. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099.
20. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000;23:35-43.
21. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS. 1998;12:F167-F173.
22. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation. 1999;100:700-705.
23. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS. 2000;14:51-57.
24. Roberts AD, Muesing RA, Parenti DM, et al. Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients. Clin Infect Dis. 1999;29:441-443.
25. Koppel K, Bratt G, Eriksson M, et al. Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection. Int J STD AIDS. 2000;11:451-455.
26. Hernandez I, del Rio C, Folch E, et al. Lipid abnormalities among PI-treated women may be due to excess production of Apo C-III. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Abstract 751.
27. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy: results from the DAD study. AIDS. 2003;17:1179-1193.
28. Savès M, Raffi F, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2002;34:1396-1405.
29. Negredo E, Ribalta J, Paredes R, et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS. 2002;16:1383-1389.
30. van Leth F, Phanuphak P, Gazzard B, et al. Lipid changes in a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Abstract 752.
31. Van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS. 2001;15:2407-2414.
32. Gallant JE, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis. 2003;37:944-950.
33. Piliero PJ. Atazanavir: a novel HIV-1 protease inhibitor. Expert Opin Investig Drugs. 2002;11:1295-1301.
34. Sanne I, Piliero P, Squires K, et al. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003;32:18-29.
35. Nieto-Cisneros L, Zala C, Fessel WJ, et al. Antiviral efficacy, metabolic changes and safety of atazanavir (ATV) versus lopinavir/ritonavir (LPV/ RTV) in combination with two NRTIs in patients who have experienced virological failure with prior PI-containing regimens: 24 week results from BMS AI424-043. Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris. Abstract 117.
36. Hedblad B, Nilsson P, Engstrom G, et al. Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death. Diabet Med. 2002;19:470-475.
37. Tsiodras S, Mantzoros C, Hammer S. Effects of protease inhibitors on hyperglycemia, hyperlipidemia and lipodystrophy: a 5-year cohort study. Arch Intern Med. 2000;160:2050-2056.
38. Wall JL, David M, Fichtenbaum CJ. The risk of ischemic cardiovascular disease is significant in persons with HIV infection. Presented at the 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle. Abstract 695.
39. Law M, Friis-Møller N, Weber R, et al. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med. 2003;4(1): 1-10.
40. El-Sadr W, Neaton J, Neuhaus J, Gordin F. Comparison of risk factors for coronary heart disease among men and women enrolled in the SMART Study (CPCRA 065). Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Abstract 745.
41. Savès M, Chêne G, Ducimetière P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis. 2003;37:292-298.
42. Ryan H, Wortley PM, Easton A, et al. Smoking among lesbians, gays, and bisexuals: a review of the literature. Am J Prev Med. 2001;21:142-149.
43. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104:257-262.
44. Maggi P, Serio G, Epifani G, et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS. 2000;14: F123-F128.
45. Pan A, Seminari E, Voltini G, et al. Intima media thickness as cardiovascular risk marker in HIV-positive patients treated and untreated with protease inhibitors. Antivir Ther. 2000;5(suppl 5):16.
46. Hsue P, Lo J, Franklin A, et al. Increased atherosclerotic progression in patients with HIV: the role of traditional and immunologic risk factors. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Abstract 139Lb.
47. Duong M, Cottin Y, Piroth L, et al. Exercise stress testing for detection of silent myocardial ischemia in human immunodeficiency virus-infected patients receiving antiretroviral therapy. Clin Infect Dis. 2002;34:523-528.
48. Rickerts V, Brodt H, Staszewski S, et al. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1999: the Frankfort HIV-cohort study. Eur J Med Res. 2000;5:329-333.
49. Friis-Moller N, Sabin CA, Weber R, et al, for the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
50. Iloeje U, Yuan Y, Tuomari A, et al. Protease inhibitors may increase risk of cardiovascular disease in HIV-infected patients. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Abstract 746.
51. Mary-Krause M, Cotte L, Simon-Coutellier A, et al. Myocardial infarction (MI) in HIV seropositive men in the era of HAART treatments in France. Presented at the XIII International AIDS Conference; July 9-14, 2000; Durban, South Africa. Abstract WePeB4231.
52. Barbaro G, Di Lorenzo G, Giancaspro G, et al. Incidence of coronary artery disease in HIV-infected patients receiving or not protease inhibitors: a randomized multicenter study. Presented at the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract WeOrB1307.
53. Jütte A, Schwenk A, Franzen C, et al. Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment? AIDS. 1999;13:1796-1797.
54. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet. 2002;360:1747-1748.
55. Coplan PM, Nikas AA, Leavitt RY, et al. Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trials. AIDS. 2001;15:1584-1586.
56. Klein D, Hurley L, Sidney S. Do protease inhibitors increase the risk for coronary heart disease among HIV-positive patients? Additional follow-up. Presented at the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 4, 2000; San Francisco. Abstract 33.
57. Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348:702-710.
58. David MH, Hornung R, Fichtenbaum CJ. Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clin Infect Dis. 2002;34:98-102.
59. Moore RD, Keruly JC, Lucas G. Increasing incidence of cardiovascular disease in HIV-infected persons in care. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003. Boston. Abstract 132.
60. Klein D, Hurley L. Hospitalizations for coronary heart disease and myocardial infarction among men with HIV-1 infection: additional follow-up. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Abstract 747.
61. National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf. Accessed August 2003.
62. Dubé MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-627.
63. Batterham MJ, Brown D, Workman C. Modifying dietary fat intake can reduce serum cholesterol in HIV-associated hypercholesterolemia. AIDS. 2003;17:1414-1416.
64. Fichtenbaum CJ, Gerber JG, Rosenkrantz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG study A5047. AIDS. 2002;16:569-577.
65. Carr RA, Andre AK, Bertz RJ, et al. Concomitant administration of ABT-378/ritonavir (ABT-378/r) results in a clinically important pharmacokinetics (PK) interaction with atorvastatin (ATO) but not pravastatin (PRA). Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000; Toronto. Abstract 1644.
66. Moyle GJ, Lloyd M, Reynolds B. Dietary advice with or without pravastatin for the management of hypercholesterolemia associated with protease therapy. AIDS. 2001;15:1503-1508.
67. Narayan S, Hawley N, Bradley AD. Attenuated T-lymphocyte response in HIV therapy in individuals receiving HMG-CoA reductase inhibitors. HIV Clin Trials. 2003;4:164-169.
68. Henry K, Melroe H, Huebesch J, et al. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet. 1998;352:1031-1032.
69. Calza L, Manfredi R, Chiodo F. Statin and fibrates for the treatment of hyperlipidemia in HIV-infected patients receiving HAART. AIDS. 2003;17:851-859.
70. Schwartz ML. Severe reversible hyperglycemia as a consequence of niacin therapy. Arch Intern Med. 1993;153:2050-2052.
71. Murphy RL, Smith WI. Switch studies: a review. HIV Med. 2002;3:146-155.
72. Barreiro P, Soriano V, Blanco F, et al. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS. 2000;14:807-812.
73. Ruiz L, Negredo E, Domingo P, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy. J Acquir Immune Defic Syndr. 2001;27:229-236.
74. Moyle GJ, Baldwin C, Langroudi B, et al. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr. 2003;33:22-28.
75. Dressman J, Kincer J, Matveev SV, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent choesteryl ester accumulation in macrophages. J Clin Invest. 2003;111:389-397.
76. Tabib A, Leroux C, Mornex JF, Loire R. Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus-positive patients. Coron Artery Dis. 2000;11:41-46.
77. Notice to Physicians: Important interim results from a phase in randomized, double-blind comparison of three protease-inhibitor-sparing regimens for the initial treatment of HIV infection (AACTG Protocol A5095). Available at: http://www.niaid.nih.gov/daids/pdf/aactg_a5095.pdf. Accessed January 2004.
78. Lafeuillade A, Jolly P, Chadapaud S, et al. Evolution of lipid abnormalities in patients switched from stavudine- to tenofovir-containing regimens. J Acquir Immune Defic Syndr. 2003;33:544-546.
79. Staszewski S, Gallant JE, Pozniak AL, et al. Favorable metabolic profile for tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine and efavirenz in antiretroviral naive patients: 96-week interim results. Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris. Abstract 562.
80. Domingo P, Labarga P, Llibre JM, et al. Dyslipidaemia improvement in patients switching from D4T to tenofovir (recovery study). Presented at the 9th European AIDS Conference (EACS); October 25-29, 2003; Warsaw. Abstract F8/5.